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the southern region of the USA had a higher costs compared to east, Midwest, and 
west regions (paid amount $3720 vs $3592 vs $3673 vs $2613). ConClusions: The 
cost of Teriflunomide treatment for RRMS patients is higher and costing the health 
plan around $3552 per month. The cost of the drug treatment was higher in southern 
of the USA and males were paying more in general.
PND6
Cost-Utility ANAlysis of NAtAlizUmAb As first-liNe treAtmeNt 
of HigHly-ACtive relAPsiNg-remittiNg mUltiPle sClerosis iN tHe 
brAziliAN PUbliC HeAltHCAre system
Alves J, Machado M
Biogen Idec, São Paulo, Brazil
objeCtives: To assess the cost-effectiveness of natalizumab (NAT) as first-line 
treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (HARRMS) ver-
sus pooled interferon-beta (IFN) and glatiramer acetate (GA) from the Brazilian 
Public Healthcare (SUS) perspective. Natalizumab is currently only reimbursed for 
RRMS patients that failed therapy with IFN and GA. Currently, no guidance exist 
for patients with HARRMS in Brazil. Methods: A microsimulation model was 
developed with yearly cycles over a 20-year time horizon. Four different treatment 
sequences are included in the model: T1= NAT-IFN-GA, T2= NAT-GA-IFN, T3= IFN-
GA-NAT and T4= GA-IFN-NAT, allowing treatment failures [i.e., > = 1-point increase 
in the Expanded Disability Status Scale (EDSS)] to alternate therapies. Patients may 
experience EDSS progression, relapses, remain stable, discontinue treatment, or 
die. Natural history was parameterized from the 2005 UK MS Survey. Efficacy, utili-
ties and safety/discontinuation data were derived from respective pivotal trials. 
HARRMS was defined as > 2 disabling relapses in previous year and > 1 gadolinium-
enhancing lesions or a significant increase in T2 lesions. Direct costs were from gov-
ernment reimbursement lists (i.e., DATASUS, BPS, SIGTAP), discounted at 5% yearly, 
and reported in Brazilian currency (1BRL= 0.35USD). Consequences were assessed 
in quality adjusted life years (QALY). Monte-Carlo first-order was used. Results: 
Natalizumab as first-line for HARRMS (sequences T1 and T2) was considered cost-
effective in comparison to sequences T3 and T4 (standard practice). Total costs 
(K= thousands) and QALYs for each treatment arm were: T4= BRL187K/5.43QALY, 
T3= BRL203K/5.41QALY, T2= BRL227K/7.02QALY and T1= BRL228K/7.01QALY. The 
incremental cost-effectiveness ratio (ICER) for T1 and T2 relative to the least costly 
sequence (T4) were BRL25,258/QALY and BRL26,324/QALY respectively, and consid-
ered acceptable assuming a threshold of 3x the national gross domestic product 
(GDP) per capita (~BRL70,000/QALY). ConClusions: Since patients with HARRMS 
experience higher relapse rates and faster disability progression than the general 
RRMS population, natalizumab as first-line option is cost-effective and brings addi-
tional benefits to Brazilian patients.
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soCioeCoNomiC imPACt of immUNoglobUliN rePlACemeNt tHerAPy for 
PrimAry immUNoDefiCieNCy PAtieNts oN tHe HeAltH PUbliC system iN 
brAzil: A siNgle CeNter stUDy
Carmo EV1, Correa M1, Mazzucchelli JL2, Tavares L2, Damasceno E2, Costa-Carvalho BT2
1Baxter Hospitalar Ltda, São Paulo, Brazil, 2Federal University of São Paulo, São Paulo, Brazi
objeCtives: Evaluate the costs and socioeconomic aspects of Immunoglobulin 
replacement therapy in patients with Primary Immunodeficiency (PID) treated 
at a Public health clinic in Brazil. Methods: Transversal study with 42 patients 
who are being treated with intravenous immunoglobulin (IVIG) at the Division 
of Allergy Clinical Immunology and Rheumatology, Federal University Federal of 
São Paulo. Costs data were obtained from patient charts and Ministry of Health 
public reimbursement prices during the year of 2014. Socioeconomic data were 
obtained from a questionnaire answered by patients or their caregivers. A cost-
minimization modeling was performed comparing intravenous and subcutaneous 
routes. Results: Median patient age was 17 years old (6 months - 58 years) and 
71% were male. Mean IVIG dose was 639 mg/kg (400-1000 mg) under a 4 weeks 
regimen. Seventy-one percent of patients used public transportation, with mean 
daily expenditure (MDE) of R$ 19 and median duration of locomotion (MDL) of 4h 
(2:00-9:30); 25% used their own vehicle, with MDE of R$ 39 (0-100.00) and MDL of 
3:00h (0:45 to 4:45); 4% utilized an ambulance for transportation, with a MDL of 9:45h 
(5:00-14:30). Mean direct medical costs (drugs, infusion sets and health professional 
and administrative salaries) were R$ 2,298/patient/year for intravenous adminis-
tration. Thirteen school/ workdays were lost per year in this group, with a mean 
impact of RS 796/year/patient. Total cost (mean) of IVIG replacement was R$ 34,169/
patient/year while for subcutaneous route the cost calculated was R$ 32,245year (an 
R$ 1.833 difference). A 3 year cost minimization modeling comparing intravenous 
to subcutaneous route showed an average difference of R$ 1,128 per patient/year 
favoring the subcutaneous route. ConClusions: This is first study evaluating the 
cost of immunoglobulin replacement therapy in PID patients in Brazil. The cost-
minimization analysis showed that the choice of subcutaneous route could bring 
benefits for the Public Health System.
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AN ANAlysis of meDiCiNe ProCUremeNt for AlzHeimer’s DiseAse iN 
brAzil from feDerAl PUrCHAses
Costa RD1, Osorio-de-Castro CG2, Silva RM2, Maia AA3, Ramos MC3, Caetano R4
1Instituto de Medicina Social, Rio de Janeiro, Brazil, 2Escola Nacional de Saúde Pública Sergio 
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objeCtives: To describe the profile of medicines procurement for Alzheimer’s 
disease (AD) in a Brazilian federal database. Methods: This study investigated 
procurement of medicines for AD in the Sistema Integrado de Administração de 
Serviços Gerais (SIASG). A profile of purchases, expenditures and prices from 2008 
to 2013 was drawn. The following medicines used for treatment of AD — donepezil, 
galantamine, rivastigmine and memantine — in several dosage forms were investi-
gated, including those not present in the Brazilian guidelines (PCDT). The extracted 
contributed up to 2.4% of the total cost for meningococcal disease in Chile, in 
contrast to 1.7% and 1.3% of the total cost estimated in Colombia and Panama, 
respectively. ConClusions: Findings of this study underscore the importance of 
meningococcal disease in the region in terms of cost. Future research should focus 
on more detailed investigation of costs of meningococcal cases and outbreaks from 
the societal perspective.
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HeAltHCAre Costs AssoCiAteD witH PAtieNts DiAgNoseD witH 
relAPsiNg remittiNg mUltiPle sClerosis
Greene N1, Greene M2
1CPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA
objeCtives: The objective of this study is to assess the health care costs associated 
with Disease Modifying Therapies (DMTs) for patients diagnosed with Relapsing 
Remitting Multiple Sclerosis (RRMS). Methods: A large US administrative retro-
spective claims database was used to identify patients diagnosed with RRMS and 
were prescribed DMTs between January 2010 to December 2012 were included in 
the study. All patients were ≥ 18 years of age and continuously enrolled in the same 
health plan for at least a year. Descriptive statistics were performed on the data 
where appropriate. Results: There were a total of 741,065 patients that met the 
study inclusion criteria. Patients on average were charged $4161.40 ± 2817.59 for 
their DMTs treatment during the study period. However, the allowed amount by 
the health plan was $3681.33 ± 1847.82 and the actual paid amount was $3580.63 
± 1859.14. On average, patient’s deductible was $21.72 ± 228.50 and patient co-
payment was $82.94 ± 285.47. For patients whose prescription was on their health 
plans formulary paid on average higher costs compared to patients who were not 
(paid amount $3595 vs $3370; allowed amount $3686 vs 3493). Even though most 
of the patients were females, but they had overall lower costs compared to males 
(amount allowed $3677 vs $3689; paid amount $3576 vs $3590; deductible $21 vs $23; 
co-payment $82 vs $84). Patients who received treatment in the Midwest region of 
the USA had a higher costs compared to east, south, and west regions (paid amount 
$3672 vs $3596 vs $3468 vs $3461). ConClusions: The mean cost of treatment with 
any DMTs for the treatment of RRMS patients is $4161. The drug formulary status 
did not play a role in determining overall healthcare costs. Females and patients 
from Midwest region generally had higher costs.
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HeAltH CAre resoUrCe UtilizAtioN AssoCiAteD witH PeDiAtriC 
PAtieNts DiAgNoseD witH relAPsiNg remittiNg mUltiPle sClerosis
Greene N1, Greene M2
1MCPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA
objeCtives: The objective of this study is to assess the health care resource utiliza-
tion and costs associated with Disease Modifying Therapies (DMTs) for pediatric 
patients diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS). Methods: 
A large US administrative retrospective claims database was used to identify 
patients diagnosed with RRMS and were prescribed DMTs between January 2010 to 
December 2012 were included in the study. All patients were ≤ 17 years of age and 
continuously enrolled in the same health plan at least for a year. Results: There 
were a total of 359 patients that met the study inclusion criteria and they were on 
the following DMTs: Gilenya (N= 7 (1.9%)), Extavia (N= 17 (4.7%)), Rebif (N= 32 (8.9%)), 
Copaxone (N= 117 (32.6%)), Avonex (N= 108 (30.1%)), and Betaseron (N= 78 (21.7%)). 
Patients on average were charged $3750.58 ± 1438.26 for their DMTs treatment dur-
ing the study period. However, the allowed amount by the health plan was $3547.05 
± 1380.56 and the actual paid amount was $3355.10 ± 1510.97. On average, patient’s 
deductible was $56.47 ± 401.03 and patient co-payment was $144.57 ± 371.65. For 
patients whose prescription was on their health plans formulary paid on average 
higher costs compared to patients who were not (paid amount $3406 vs $3223; 
allowed amount $3641 vs $3309). Even though most of the patients were females, 
but they had overall lower costs compared to males (amount allowed $3311 vs 
$3924; paid amount $3126 vs $3721; deductible $2.5 vs $155; co-payment $193 vs 
$66). Patients who received treatment in the east region of the USA had a higher 
costs compared to Midwest, south, and west regions (paid amount $3764 vs $3425 vs 
$3504 vs $3243). ConClusions: Costs were high for males and formulary status of 
the DMTs did not have an impact on the amount paid by the patients.
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HeAtlH CAre Costs AssoCiAteD witH PAtieNts DiAgNoseD witH 
relAPsiNg remittiNg mUltiPle sClerosis tAkiNg oNCe DAily 
teriflUNomiDe tAblets iN tHe UNiteD stAtes
Greene N1, Greene M2
1MPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA
objeCtives: The objective of this study is to assess the health care costs associ-
ated with Teriflunomide treatment for patients diagnosed with relapsing remitting 
multiple sclerosis (RRMS) in 2012 in the US Methods: A large US administrative 
retrospective claims database was used to identify patients diagnosed with RRMS 
and were prescribed Terfilunomide between September 2012 to December 2012 were 
included in the study. All patients were ≥ 18 years of age and continuously enrolled 
in the same health plan for a year. Descriptive statistics and chi-square tests were 
performed on the data. Results: There were a total of 157 patients that met the 
study inclusion criteria. Patients on average were charged $3816.90 ± 1702.83 for 
their treatment with Teriflunomide during the study period. However, the allowed 
amount by the health plan was $3635.28 ± 1314.56 and the actual paid amount was 
$3552.75 ± 1320.71. On average, patient’s deductible was $12.81 ± 96.33 and patient 
co-payment was $84.66 ± 184.95. For patients whose prescription was on their health 
plans formulary were charged less but paid more on the deductible and co-payment 
compared to patients who were not (charged amount $3646 vs $3829; deductible $14 
vs $11; co-payment $122 vs $63) on the formulary. Even though most of the patients 
were females, but they had overall lower costs compared to males (amount allowed 
$3475 vs $4057; paid amount $3391 vs $3980). Patients who received treatment in 
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NAtioNAl estimAtes of PrevAleNCe AND PAtterNs of PsyCHotroPiC 
PolyPHArmACy AmoNg elDerly iNDiviDUAls witH PArkiNsoN’s DiseAse 
iN NUrsiNg Home AND Home HeAltHCAre settiNgs iN tHe UNiteD stAtes
Bhattacharjee S, Goldstone L, Warholak T
The University of Arizona, Tucson, AZ, USA
objeCtives: Some elderly individuals with Parkinson’s disease (PD) may suffer 
from more than one psychiatric comorbidity, which necessitates the use of concur-
rent psychotropic medications. To the best of the author’s knowledge there are no 
nationally representative estimates of psychotropic polypharmacy among elderly 
individuals with PD in the United States. Therefore, the primary objective of this 
study was to examine the prevalence and patterns of psychotropic polypharmacy 
among elderly individuals with PD. Methods: A retrospective, cross-sectional 
study design with 2004 National Nursing Home Survey (NNHS) and 2007 National 
Home and Hospice Care Survey (NHHCS) data was used. The analytic sample 
included elderly (age ≥ 65 years) individuals with PD (identified by ICD-9-CM code 
of 332.xx). Antidepressants, antipsychotics, sedative/hypnotics, and anti-anxiety 
medications constituted the psychotropic medication classes. Concurrent use of 
two or more psychotropic medications was classified as psychotropic polyphar-
macy. National estimates of psychotropic medication use were obtained by using 
SAS survey procedures. Results: National estimate of approximately 93,648 [95% 
Confidence Interval (CI), 86535 – 100,761] and 37,439 (95% CI, 25,910 – 48,968) elderly 
individuals with PD resided in nursing homes and home health settings respec-
tively. Among elderly nursing home residents with PD, the nationally representative 
prevalence of psychotropic polypharmacy was 26.28% (95% CI, 22.81% – 29.75%), 
whereas, it was 21.36% (95% CI, 8.12% – 34.6%) in the home health setting. Use of 
antidepressant medications constituted the majority of the psychotropic medica-
tion use among both nursing home (48.91%, 95% CI, 44.9% – 52.8%) and home health 
(40.98%, 95% CI, 25.37% - 56.61%) residents with PD. Nearly one-third (31.26%, 95% 
CI, 27.6% - 34.9%) nursing home residents with PD were prescribed antipsychotic 
medications among whom less than one-fourth had a documented psychotic diag-
nosis. ConClusions: These findings underscore the importance of evidence-based 
prescribing when psychotropic medications are used in elderly individuals with PD 
to reduce unnecessary polypharmacy.
PND12
CHArACteristiCs of PAtieNts witH relAPsiNg remittiNg mUltiPle 
sClerosis tAkiNg oNCe DAily teriflUNomiDe tAblets iN tHe UNiteD 
stAtes
Greene N1, Greene M2
1MCPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA
objeCtives: Teriflunomide oral tablets were approved in the United States (US) in 
September 2012 for the treatment of relapsing remitting multiple sclerosis (RRMS). 
The objective of this study is to assess the characteristics of RRMS patients tak-
ing Teriflunomide tablets in 2012 in the US. Methods: A large US administra-
tive retrospective claims database was used to identify patients diagnosed with 
RRMS and were prescribed Terfilunomide between September 2012 to December 
2012 were included in the study. All patients were ≥ 18 years of age and continu-
ously enrolled in the same health plan for a year. Descriptive statistics and chi-
square tests were performed on the data and statistical significance level was set 
a priori at 0.05. Results: There were a total of 157 patients that met the study 
inclusion criteria. Of these, 114 (72.6%) were females, mean age was 50.9±9.7 years, 
and females were older than males (51.4 vs 49.5 years) with no statistical signifi-
cance different between them. Thirty three percentage of the patients were from 
Midwest, 30.6% were from East, 26.1% from south and 10.2% from West of the USA. 
Twenty eight percentage of the patient’s prescription was under their health plan 
formulary and received an average of supply of 29.4 ± 8.8 days. Majority (61.1%) of 
the patients was under group coverage and 55.4% of patients were diagnosed with 
having mental health problems. Males enrolled continuously (60.21 ±21.8 vs 52.5 ± 
28.9 months) much longer than females in the same health plan. But, females had 
a higher number of total claims (514.9 ± 443 vs 391.4 ± 307.6) during the enrollment 
period. ConClusions: Majority of the patients taking Terfilunomide was females 
and had more number of claims related to MS than males. And, majority of the 
patients were dispensed Terfilunomide for only one month supply.
PND13
Costo efeCtiviDAD De lA terAPiA iNmUNomoDUlADorA eN esClerosis 
mUltiPle tiPo reCAíDA remisioN: bUsqUeDA sistemátiCA De lA 
literAtUrA
Sánchez E
Universidad Nacional de Colombia, Bogotá, Colombia
objeCtivos: Llevar a cabo una revisión de la evidencia disponible de costo-efec-
tividad de la terapia inmunomoduladora con medicamentos modificadores de la 
enfermedad aprobados en Colombia para el tratamiento de la Esclerosis Múltiple 
(EM) tipo recaída remisión. MetodologíAs: Búsqueda sistemática de evaluaciones 
económicas en las bases de datos PUBMED y EMBASE a través de una estrategia 
de búsqueda estructurada en pacientes adultos con diagnóstico confirmado de 
esclerosis múltiple tipo recaída remisión bajo tratamiento con IFN B, Acetato de 
Glatirámero, Natalizumab y/o fingolimod. Se incluyeron estudios de costo-efec-
tividad y/o costo-utilidad y se excluyeron estudios de análisis de impacto presu-
puestal y de costo de la enfermedad. Se llevó a cabo la evaluación de la calidad 
de los estudios mediante la herramienta Quality of Health Economics Studies 
(QHES) ResultAdos: Se analizaron 30 estudios identificados que contenían los cri-
terios de inclusión preestablecidos. El 83% fueron desarrollados en Estados Unidos 
y Europa. El 90% de los estudios publicados corresponde a países desarrollados y el 
10% a países en vía de desarrollo. Los principales resultados en salud fueron Calidad 
de Vida, número de recaídas evitadas y años libres de recaídas. Siendo la EM una 
information included date of purchase; quantity of units purchased; unit price; 
responsible body; form of acquisition (tendering or waivered emergency purchase) 
and justification for purchase (regular use or health litigation). Unit prices were 
deflated to December 2013 by the IPCA (Brazilian Pricing Index) to allow compara-
bility and evaluation of trends. Results: More than 47 million units of medicines 
for AD were bought and expenditures reached 90.1 million reais, with rivastigmine 
purchases in the forefront. Medicines not present in the guidelines represented 
3% of expenditures and purchases associated to health litigation were negligi-
ble. The Ministry of Defense was the largest buyer of medicines not included in 
the guidelines. Over the entire period, a reduction of corrected weighted average 
prices of PCDT and non-PCDT medicines was observed. ConClusions: We noted 
a significant increase in the amount of medicine purchases over time. Updates on 
PCDT, changes in medicines financing and procurement, and the establishment of 
Productive Development Partnerships may have contributed with the scale-up of 
AD treatment availability. The reduction of lawsuits demanding medicines suggests 
normalization of medicine procurement mechanisms for these drugs. The resources 
consumed with non-PCDT medicines increased in the period.
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A systemAtiC literAtUre review of globAl eCoNomiC evAlUAtioNs of 
rAsAgiliNe for PArkiNsoN’s DiseAse
Grubb E1, Trautman H2, Gandhi SK3, Gennero R3
1Teva Pharmaceuticals, Overland Park, KS, USA, 2Aventine Consulting LLC, Marblehead, MA, 
USA, 3Teva Pharmaceuticals Inc, Malvern, PA, USA
objeCtives: This systematic review is conducted to investigate the impact of 
rasagiline on economics of care for patients with PD. Methods: A literature 
search using the online version of Index Medicus identified relevant publications, 
abstracts, technology assessments of rasagiline using search terms; title: rasagiline 
and Parkinson* AND economic OR budget OR cost; language: English; publication 
dates 01/01/2009 to 01/30/2015. In addition, websites were searched for health tech-
nology assessments. Results: A total of 15 studies (7 cost models, 1 economic 
database analysis and 7 resource utilization studies) were eligible for inclusion. The 
four US based cost effectiveness models suggest that initiating treatment (tx) with 
rasagiline had lower costs ($1600) and higher expected QALYs (0.0608) over 5 years 
compared with ropinirole XL; total medical and pharmacy costs were $115,653 less 
per patient for rasagiline vs standard of care over 25 years. In addition, initiating tx 
with rasagiline was cost effective relative to generic ropinirole (CE ratio of $25,939 
per QALY); and a US cost-utility analysis showed adjunctive use of rasagiline with 
levodopa and carbidopa/levodopa/entacapone were both dominant strategies over 
levodopa monotherapy. In a Mexico-based model using a 5-year time horizon the 
cost per QALY for rasagiline was $33,400 (Mexico peso). Medication and adverse 
event costs were also evaluated in a Russian model. Observational study results (8) 
were based on US, UK and Croatian data. US studies results comparing rasagiline 
to selegiline show fewer hospitalizations (1.119 vs 2.113, p= 0.013) shorter length 
of stay (2.762 vs 5.556, p= 0.014) and lower likelihood of emergency department 
visits (OR= 0.791, 95% CI 0.677 to 0.926) with rasagiline. ConClusions: Rasagiline 
was found cost effective across multiple countries compared with commonly used 
PD medications. The beneficial impact of rasagiline on resource utilization in the 
observational studies highlights the real world potential of rasagiline to result in 
economic benefits to healthcare systems.
NeUrologiCAl DisorDers – Patient-reported outcomes & Patient Preference 
studies
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ADHereNCe AND PersisteNCe AmoNg PAtieNts treAteD witH first-liNe 
tHerAPies for relAPsiNg-remittiNg mUltiPle sClerosis iN brAzil
Gulart A1, Teich V2, Oliveira R3, Amarante D3, Alves J3, Machado M3
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objeCtives: To estimate the levels of adherence and persistence of patients 
with Relapsing-Remitting Multiple Sclerosis (RRMS) and treated with platform 
therapies in Brazil. Methods: DATASUS, a nation-wide, anonymized, health-
care claims database was used as primary data source. Naïve patients starting 
on one of the platform therapies for RRMS, between January and June 2013 were 
followed for at least 13 months (up to 18), until September 2014) after the first 
entry in DATASUS (considered for this analysis as treatment initiation). Therapies 
included intramuscular (IM) interferon beta-1a (IFNβ -1a), subcutaneous (SC) 
IFNβ -1a, IFNβ -1b, and glatiramer acetate (GA).Adherence was measured as medi-
cation possession ratio (MPR), calculated as the proportion of months patients 
possessed their therapies independently of drug change until the end of the ana-
lyzed period, where MPR> 0.80 was considered adherent. Persistence was time in 
months from initiation date until a 30-day gap in therapy or the last claim during 
follow-up. Chi-square assessed the association between treatments and time on-
therapy. Median difference between MPR was assessed through Kruskal-Wallis’ 
Method. Analyses were performed using R, version 3.1. Results: Total number 
of patients was 1,052: IM-IFNβ -1a (N= 351, 33.4%); IFNβ -1b (N= 145, 13.8%); GA 
(N= 264, 25.1%); and SC-IFNβ -1a (N= 292, 27.8%). MPR> 0.80 was significantly higher 
(p< 0.001) in the IM-IFNβ -1a group (71.8%) versus IFNβ -1b (58.6%), GA (65.5%), and 
SC-IFNβ -1a (63.7%). There were no consistent differences in persistence between 
the groups. ConClusions: While there are limitations in measuring adherence 
even in controlled trials, MPR seems to be appropriate in real life scenario. Patients 
initiating treatment with IM-IFNβ -1a showed better adherence than those initiat-
ing with other platform therapies for RRMS in Brazil. The literature reports simi-
lar efficacy and safety profile among platform therapies, however, they differ in 
terms of administration route and dose scheduling. Better adherence results for 
IM-IFNβ -1a may be associated with dosing regimen and convenient administration 
from an auto-injector device.
